Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.76 +0.38 (+0.90%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

August 26, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off

August 25, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Integer Holdings, Astrana Health, Surgery Partners, IQVIA, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know

August 22, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested...

Via StockStory

Topics Economy

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off

August 21, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation ↗

August 18, 2025

Supernus Pharmaceuticals (SUPN) offers strong growth, solid profitability, and fair valuations, making it an ideal pick for Affordable Growth investors.

Via Chartmill

Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks

August 17, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

August 17, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers

August 14, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade

August 12, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The...

Via StockStory

1 Momentum Stock for Long-Term Investors and 2 Facing Challenges

August 11, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media...

Via StockStory

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)

August 10, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today

August 06, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 14.4% in the afternoon session after the company posted strong second-quarter earnings that beat expectations...

Via StockStory

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales

August 05, 2025

Via StockStory

Supernus Announces Second Quarter 2025 Financial Results

August 05, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect

August 03, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday afternoon. Here’s what investors should know.

Via StockStory

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

July 31, 2025

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to...

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today

July 30, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its...

Via StockStory

Topics Lawsuit

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

July 28, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

July 24, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

July 22, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today

July 18, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care...

Via StockStory

Topics Artificial Intelligence Lawsuit

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals ↗

July 18, 2025

SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is an undervalued stock with strong profitability, no debt, and steady growth—making it a potential pick for value investors.

Via Chartmill

1 Stock Under $50 with Exciting Potential and 2 to Turn Down

July 14, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution

July 10, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

June 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗

June 22, 2025

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Via Stocktwits

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News ↗

June 17, 2025

Via Benzinga

June 17, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.